Reported Thursday, Calliditas Therapeutics And Viatris Initiate Phase III Clinical Trial Of Nefecon For IgA Nephropathy In Japan

7/5/24 2:42:47 AM ET

$CALT

$VTRS

Biotechnology: Pharmaceutical Preparations

Health Care

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $CALT alert in real time by email

The clinical trial is a bridging study requiring a limited number of Japanese patients to participate in a study similar in design to that of the global NefIgArd trial. IgA nephropathy is a designated retractable disease in Japan, with an estimated 33,000 patients in Japan* assumed to be suffering from this disease and with limited treatment options for IgAN patients in this country.

Get the next $CALT alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CALT
$VTRS

Company	Date	Price Target	Rating	Analyst
Viatris Inc. $VTRS	7/19/2024	$15.00	Buy	Jefferies
Viatris Inc. $VTRS	10/23/2023	$13.00 → $9.00	Neutral → Underperform	BofA Securities
Viatris Inc. $VTRS	6/23/2023	$11.00	Equal Weight → Underweight	Barclays
Calliditas Therapeutics AB $CALT	6/20/2023	$60.00	Buy	H.C. Wainwright
Viatris Inc. $VTRS	4/24/2023	$11.00	Overweight → Equal Weight	Barclays
Calliditas Therapeutics AB $CALT	3/1/2023	$18.00	Neutral	Guggenheim
Viatris Inc. $VTRS	2/17/2023	$16.00 → $14.00	Outperform → Market Perform	BMO Capital Markets
Viatris Inc. $VTRS	1/27/2023	$13.00 → $15.00	Hold → Buy	Jefferies

More analyst ratings

$CALT
$VTRS
Press Releases

Fastest customizable press release news feed in the world

Viatris Reports Third Quarter Financial Results for 2024
PITTSBURGH, Nov. 7, 2024 /PRNewswire/ -- Total Revenues of $3.8 Billion and Operational Revenue Growth of ~3% on a Divestiture-Adjusted Basis Demonstrate Strength of Company's Base Business[1] Strong New Product Revenues of $133 Million Drove Growth Across Segments U.S. GAAP Net Earnings were $95 Million; Adjusted EBITDA Grew ~4% to $1.3 Billion on a Divestiture-Adjusted Basis; U.S. GAAP Diluted EPS was $0.08 per Share; Adjusted EPS Grew ~6% to $0.75 per Share on a Divestiture-Adjusted Basis[2] Repaid ~$1.9 Billion of Debt, Expects to Achieve its Long-Term Gross Leverage Target of ~3.0x by end of the Year[3] Entered into Exclusive Licensing Agreement for
11/7/24 6:59:00 AM ET
$VTRS
Biotechnology: Pharmaceutical Preparations
Health Care
Viatris Announces Third Quarter 2024 Dividend
PITTSBURGH, Nov. 5, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) today announced that on November 4, 2024, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The dividend is payable on December 13, 2024, to shareholders of record as of the close of business on November 22, 2024. About Viatris Viatris Inc. (NASDAQ:VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we p
11/5/24 6:59:00 AM ET
$VTRS
Biotechnology: Pharmaceutical Preparations
Health Care
Viatris Named to Forbes' World's Top Companies for Women 2024 List
PITTSBURGH, Oct. 29, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that it has been named to Forbes' World's Top Companies for Women 2024 List. This award is presented in collaboration with Statista, the world-leading statistics portal and industry ranking provider. "At Viatris, diverse perspectives drive innovation and our ability to make an impact, as we empower people worldwide to live healthier at every stage of life," said Andrew Enrietti, Chief People Officer, Viatris. "Being recognized on Forbes' list of the World's Top Companies for Women 2024 demonstrates our focus on investing in our people and fostering diverse talent. This accolade
10/29/24 12:00:00 PM ET
$VTRS
Biotechnology: Pharmaceutical Preparations
Health Care

$CALT
$VTRS
Financials

Live finance-specific insights

Viatris Reports Third Quarter Financial Results for 2024
PITTSBURGH, Nov. 7, 2024 /PRNewswire/ -- Total Revenues of $3.8 Billion and Operational Revenue Growth of ~3% on a Divestiture-Adjusted Basis Demonstrate Strength of Company's Base Business[1] Strong New Product Revenues of $133 Million Drove Growth Across Segments U.S. GAAP Net Earnings were $95 Million; Adjusted EBITDA Grew ~4% to $1.3 Billion on a Divestiture-Adjusted Basis; U.S. GAAP Diluted EPS was $0.08 per Share; Adjusted EPS Grew ~6% to $0.75 per Share on a Divestiture-Adjusted Basis[2] Repaid ~$1.9 Billion of Debt, Expects to Achieve its Long-Term Gross Leverage Target of ~3.0x by end of the Year[3] Entered into Exclusive Licensing Agreement for
11/7/24 6:59:00 AM ET
$VTRS
Biotechnology: Pharmaceutical Preparations
Health Care
Viatris Announces Third Quarter 2024 Dividend
PITTSBURGH, Nov. 5, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) today announced that on November 4, 2024, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The dividend is payable on December 13, 2024, to shareholders of record as of the close of business on November 22, 2024. About Viatris Viatris Inc. (NASDAQ:VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we p
11/5/24 6:59:00 AM ET
$VTRS
Biotechnology: Pharmaceutical Preparations
Health Care
Viatris to Report Third Quarter 2024 Financial Results on November 7, 2024
PITTSBURGH, Sept. 16, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) will report its third quarter 2024 financial results on Thursday, November 7, 2024, before the open of the U.S. financial markets. Chief Executive Officer Scott A. Smith and other Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results. Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for international callers. A replay of the webcast also will be available on the website. About ViatrisViatris Inc. (NASDAQ:VTRS) is a global healthcare company uniquely positioned to bridge the tradit
9/16/24 4:30:00 PM ET
$VTRS
Biotechnology: Pharmaceutical Preparations
Health Care

Viatris Appoints Rogerio Vivaldi Coelho, M.D., to Board of Directors
PITTSBURGH, June 3, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that as part of its ongoing Board refreshment efforts, Rogerio Vivaldi Coelho, M.D., has been appointed as the newest member of its Board of Directors. Dr. Vivaldi will serve as a member of the recently reestablished Science and Technology Committee of the Board of Directors. "We are pleased to welcome Dr. Vivaldi to our Board of Directors," said Melina Higgins, Chair of the Board, Viatris. "We believe his proven expertise and long track record of success will enhance the efforts of the Board across a range of areas, in particular with regards to our Science and Technology Commit
6/3/24 6:59:00 AM ET
$VTRS
Biotechnology: Pharmaceutical Preparations
Health Care
Viatris Appoints Corinne Le Goff as Chief Commercial Officer
PITTSBURGH, April 15, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that Corinne Le Goff has joined the company as Chief Commercial Officer and will become a member of the company's Executive Leadership Team, effective today. Le Goff is an accomplished biotechnology and pharmaceutical executive with more than 25 years of experience leading and building highly successful teams globally. She is a visionary and entrepreneurial leader with a strong scientific background and experience across multiple markets and therapeutic areas. Prior to joining Viatris, Le Goff was President and Chief Executive Officer of Imunon, a clinical-stage biotechnology
4/15/24 8:00:00 AM ET
$VTRS
Biotechnology: Pharmaceutical Preparations
Health Care
Calliditas Therapeutics appoints Maria Törnsén as President North America
STOCKHOLM, Jan. 7, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ:CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today announced that Maria Törnsén has been appointed to the position of President North America. Ms Törnsén will be responsible for all US based operations and will report to the CEO. Maria Törnsén has broad commercial leadership experience having spent more than 20 years in the biopharma industry in senior commercial roles. Most recently Ms Törnsén held the position of Chief Commercial Officer at Passage Bio, prior to which she was SVP General Manager US at Sarepta Therapeutics. Prior to joining Sarepta she serv
1/7/24 11:19:00 AM ET
$CALT
Biotechnology: Pharmaceutical Preparations
Health Care

Reported Thursday, Calliditas Therapeutics And Viatris Initiate Phase III Clinical Trial Of Nefecon For IgA Nephropathy In Japan

Chat with this insight

Recent Analyst Ratings for $CALT$VTRS

$CALT$VTRS Press Releases

Fastest customizable press release news feed in the world

Viatris Reports Third Quarter Financial Results for 2024

Viatris Announces Third Quarter 2024 Dividend

Viatris Named to Forbes' World's Top Companies for Women 2024 List

$CALT$VTRS SEC Filings

SEC Form 144 filed by Viatris Inc.

SEC Form 10-Q filed by Viatris Inc.

Viatris Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

$CALT$VTRS Financials

Live finance-specific insights

Viatris Reports Third Quarter Financial Results for 2024

Viatris Announces Third Quarter 2024 Dividend

Viatris to Report Third Quarter 2024 Financial Results on November 7, 2024

$CALT$VTRS Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Jefferies resumed coverage on Viatris with a new price target

Viatris downgraded by BofA Securities with a new price target

Viatris downgraded by Barclays with a new price target

$CALT$VTRS Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Officer Campbell Paul sold $346,686 worth of shares (26,925 units at $12.88), decreasing direct ownership by 18% to 126,901 units (SEC Form 4)

Director Korman Harry bought $61,252 worth of shares (4,403 units at $13.91), increasing direct ownership by 6% to 94,960 units (SEC Form 4)

Director Malik Rajiv sold $2,334,716 worth of shares (200,000 units at $11.67), decreasing direct ownership by 22% to 505,838 units (SEC Form 4)

$CALT$VTRS Market Insights

Live Market Insights

$CALT$VTRS FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

Warner Bros. Discovery & Coinbase Are Among 10 Large Cap Stocks That Shined Most Last Week (July 14-July 20): Are The Others In Your Portfolio?

Jefferies Reinstates Buy on Viatris, Announces $15 Price Target